Trial Profile

Efficacy of atorvastatin (10 and 80 mg/day) in patients with stable coronary disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atorvastatin (Primary)
Indications Coronary artery disease
Focus Pharmacogenomic; Therapeutic Use
Acronyms TNT
Sponsors Pfizer

Most Recent Events

26 Jun 2021 Results of pooled post-hoc analysis of two studies (IDEAL, NCT00159835 and TNT, NCT00327691) were presented at The International Liver Congress 2021.
05 Apr 2018 Results (n=4853) of analysis estimating individual benefit from PCSK9 inhibition in terms of months gained free of stroke or MI in statin treated patients with stable CAD published in the Heart
04 Apr 2018 Results of post-hoc analysis assessing the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial published in the Circulation

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com